Cesca Therapeutics Inc (NASDAQ:KOOL) Short Interest Down 46.1% in August

Share on StockTwits

Cesca Therapeutics Inc (NASDAQ:KOOL) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 47,400 shares, a decrease of 46.1% from the July 31st total of 88,000 shares. Based on an average daily volume of 139,000 shares, the short-interest ratio is presently 0.3 days. Approximately 2.8% of the company’s shares are short sold.

NASDAQ:KOOL traded up $0.03 on Friday, reaching $4.27. 103,600 shares of the company’s stock were exchanged, compared to its average volume of 107,004. The company has a quick ratio of 0.91, a current ratio of 1.52 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $9.16 million, a price-to-earnings ratio of -1.19 and a beta of 0.94. The business has a fifty day moving average of $3.12 and a 200-day moving average of $1.70. Cesca Therapeutics has a 52-week low of $2.10 and a 52-week high of $4.93.

Cesca Therapeutics (NASDAQ:KOOL) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.13. The company had revenue of $4.31 million for the quarter, compared to analyst estimates of $3.40 million. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. As a group, equities analysts anticipate that Cesca Therapeutics will post -0.45 earnings per share for the current year.

A number of analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $6.50 price target (up from $1.00) on shares of Cesca Therapeutics in a research note on Wednesday, August 14th. Zacks Investment Research upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Tuesday, August 20th. Finally, ValuEngine upgraded shares of Cesca Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Featured Story: What are the benefits of a balanced fund?

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.